Wells Fargo sets USD 64 target for Xenon Pharmaceuticals stock

Published on 10/20/2026 at 13:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xenon reported a USD 110.74 million second-quarter loss on August 6, 2026. Xenon Pharmaceuticals stock costs EUR 31.10 on October 20, 2026.

Pipeline milestones and financial context

Wells Fargo set a USD 64.00 target on October 16, 2026.
Xenon reported a USD 110.74 million net loss for the second quarter of 2026.
Xenon Pharmaceuticals stock traded at EUR 31.10 at 1:35 p.m. CEST at Lang & Schwarz on October 20, 2026.
Cash, cash equivalents, and marketable securities totaled USD 1.2 billion in the second quarter of 2026.

XENE, CA98420N1050, Illustration mit AI erstellt.

Xenon Pharmaceuticals (ISIN CA98420N1050) received a USD 64.00 price target from Wells Fargo after analyst Benjamin Burnett maintained a Buy rating on October 16, 2026, as Markets Insider reported. Xenon Pharmaceuticals stock was trading at EUR 31.10 at Lang & Schwarz on October 20, 2026 at 1:35 p.m. CEST.

Why the USD 64 target matters

The analyst view arrives as Xenon advances azetukalner, its lead drug candidate, through epilepsy and neuropsychiatry studies. The company describes azetukalner as a Kv7 potassium channel opener in Phase 3 development for epilepsy, major depressive disorder, and bipolar depression on its Xenon Pharmaceuticals investor page.

Financial capacity remains central to that strategy. Benzinga reported that cash, cash equivalents, and marketable securities totaled USD 1.2 billion at the end of the second quarter of 2026, funding operations into 2029. The same call covered preparation for a potential azetukalner launch and additional pain programs.

Three milestones frame the story

On August 6, 2026, Xenon reported a second-quarter adjusted loss of USD 1.11 per share versus a USD 1.16 consensus loss, according to MarketBeat. On September 17, 2026, Xenon submitted an FDA application for azetukalner in focal seizures and updated its psychiatry program.

On October 16, 2026, Wells Fargo maintained its Buy rating and set the USD 64.00 target. The sequence shows why the valuation case depends on epilepsy execution while the depression program is being reassessed.

What dates shape the next phase

The next milestones are the American Epilepsy Society meeting from December 4 through December 8, 2026, and first-half 2027 results from the X-NOVA2 depression study. Yahoo Finance reported that Xenon had paused new enrollment in late-stage depression studies after neurological and psychiatric side effects, while already enrolled patients remained active.

Stock price and investor context

Xenon combines a late-stage epilepsy opportunity with a clinical setback in depression and a substantial cash position. The USD 64.00 target from Wells Fargo is a dated analyst view, not a forecast by this article.

The further course of trading is shown by the continuously updated real-time quote of Xenon Pharmaceuticals stock.